Only a small percentage of the thousands of compounds tested during the discovery phase possess the desired activity and are now designated as “hits”.
Pre-clinical Formulation Approaches

A handful of the most promising hits are chosen for modification to improve target specificity, potency, chemical and metabolic stability, water solubility, and other pharmacological parameters

Polymeric Nanoparticle

Before anything is given to humans, safety and efficacy tests are conducted using computerized models, cells, and animals. The NanoAssemblr® Blaze was developed to bridge the gap between nanoparticle discovery and clinical development.


The development of an overall formulation strategy to support in vivo studies should be considered carefully as it can reduce cycle time and resources. This strategy must be comprehensive, encompassing early studies designed to identify and validate drug targets, to long-term toxicology studies and ultimately, to support clinical studies in humans.





Pre-Clinical Phase Solutions
NanoAssemblr Benchtop


During the Pre-Clinical stage, the NanoAssemblr® Ignite manufactures 1 – 15 mL of nanomedicine per run for continued optimization, preliminary stability studies and in vivo testing in small models.

NanoAssemblr Blaze


The dynamic volume range allows researchers to use the Blaze for in vivo studies in larger models, preclinical toxicology testing, early Chemistry, Manufacturing and Controls (CMC) studies and downstream process development.

Formulation Scientists in a Lab


Our services will provide you with a formulation and a technology transfer into a production facility that you can be confident will be suitable for clinical scale-up. PNI offers highly qualified scientist through our Formulation Solutions Team. 

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center


September 01, 2022

Scale Up Genome Editing of CAR T Cells using Lipid Nanoparticles

Read More 阅读更多 PDF

Application Note

March 15, 2022

Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Read More 阅读更多 PDF

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020


Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to...

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Ro...

Read More 阅读更多

Publication - Abstract

December 31, 2019


Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多
Resource Center 资源中心